Cargando…
In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies
Individuals with β-thalassemia or sickle cell disease and hereditary persistence of fetal hemoglobin (HPFH) possessing 30% fetal hemoglobin (HbF) appear to be symptom free. Here, we used a nonintegrating HDAd5/35++ vector expressing a highly efficient and accurate version of an adenine base editor (...
Autores principales: | Li, Chang, Georgakopoulou, Aphrodite, Newby, Gregory A., Everette, Kelcee A., Nizamis, Evangelos, Paschoudi, Kiriaki, Vlachaki, Efthymia, Gil, Sucheol, Anderson, Anna K., Koob, Theodore, Huang, Lishan, Wang, Hongjie, Kiem, Hans-Peter, Liu, David R., Yannaki, Evangelia, Lieber, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675455/ https://www.ncbi.nlm.nih.gov/pubmed/36006707 http://dx.doi.org/10.1172/jci.insight.162939 |
Ejemplares similares
-
In vivo HSC prime editing rescues sickle cell disease in a mouse model
por: Li, Chang, et al.
Publicado: (2023) -
Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
por: Paschoudi, Kiriaki, et al.
Publicado: (2023) -
In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations
por: Psatha, Nikoletta, et al.
Publicado: (2022) -
P1370: A NOVEL GENE THERAPY VECTOR FOR BETA-HEMOGLOBINOPATHIES WITH A SELECTIVE EXPANSION CASSETTE
por: Kirtsou, Alexandra, et al.
Publicado: (2023) -
Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements
por: Wang, Hongjie, et al.
Publicado: (2020)